Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00326586 |
This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: AR Antagonist (BMS-641988) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Safety Study |
Official Title: | A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer |
Enrollment: | 54 |
Study Start Date: | May 2006 |
Study Completion Date: | March 2009 |
Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: AR Antagonist (BMS-641988)
Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | |
Baltimore, Maryland, United States, 21231 | |
United States, New York | |
Memorial Sloan-Kettering Cancer Center | |
New York, New York, United States, 10021 | |
United States, Wisconsin | |
University Of Wisconsin Hospital And Clinics Laboratory | |
Madison, Wisconsin, United States, 53792 |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb ( Study Director ) |
Study ID Numbers: | CA185-002 |
Study First Received: | May 15, 2006 |
Last Updated: | August 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00326586 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |